126 13F filers hold it · +29 against the quarter before · shares held +132.4%
Holdings of 06/30
Health care sectorNasdaq
126 13F filers hold it · +29 against the quarter before · shares held +132.4%
Nantahala Capital Management holds 3.54% · −5.8pp on the report before
10/15 estimated earnings
13F filers: 126 · +29 since the quarter before · 06/30 holdings
Famous funds that held Avalo Therapeutics in their latest 13F report.
| Fund | Value | Since the quarter before |
|---|---|---|
| Mirae Asset Global ETFS HoldingsAvalo Therapeutics AVTX · 06/30 holdings | $480.5K | No quarter before |
| Holder | ||
|---|---|---|
| Nantahala Capital Management08/14 | 3.54%1,862,250 sh | −5.8pp |
| Caligan Partners08/14 | 5.9%3,163,866 sh | −1.3pp |
| Ra Capital Management08/14 | 6.3%3,483,099 sh | −3.6pp |
| Biotechnology Value Fund08/14 | 5.3%2,801,545 sh | −4.7pp |
| T. Rowe Price Investment Management08/14 | 0%3,670 sh | −9.5pp |
| Avoro Capital Advisors08/14 | 4.44%2,333,333 sh | −1.3pp |
| Deep Track Capital08/14 | 6.87%3,610,000 sh | +1.1pp |
| FMR08/07 | 10.8%5,737,966 sh | +1.1pp |
| State Street08/07 | 5.5%2,889,287 sh | First report |
| FMR08/06 | 9.7%5,100,216 sh | +3.6pp |
| BlackRock07/27 | 6.5%3,415,731 sh | First report |
| Millennium Management07/06 | 0%9,857 sh | −5.0pp |
| Commodore Capital06/18 | 9.9%5,721,109 sh | First report |
| FMR06/05 | 6.1%3,188,401 sh | −6.5pp |
| Deep Track Capital05/29 | 5.81%3,055,027 sh | +5.8pp |
| Point72 Asset Management05/26 | 5.2%2,710,817 sh | +1.7pp |
| Logos Global Management05/15 | 3.2%1,675,000 sh | −2.4pp |
| Orbimed Advisors05/15 | 2.1%475,165 sh | −4.3pp |
| Caligan Partners05/15 | 7.2%1,635,023 sh | +2.3pp |
| T. Rowe Price Investment Management05/15 | 9.5%2,162,684 sh | First report |